Literature DB >> 23178708

Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.

Kiyoshi Hasegawa1, Norihiro Kokudo, Masatoshi Makuuchi, Namiki Izumi, Takafumi Ichida, Masatoshi Kudo, Yonson Ku, Michiie Sakamoto, Osamu Nakashima, Osamu Matsui, Yutaka Matsuyama.   

Abstract

BACKGROUND & AIMS: The treatment of choice for early or moderately advanced hepatocellular carcinoma (HCC) with good liver function remains controversial. We evaluated the therapeutic impacts of surgical resection (SR), percutaneous ethanol injection (PEI), and radiofrequency ablation (RFA) on long-term outcomes in patients with HCC.
METHODS: A database constructed on the basis of a Japanese nationwide survey of 28,510 patients with HCC treated by SR, PEI, or RFA between 2000 and 2005 was used to identify 12,968 patients who had no more than 3 tumors (≤ 3 cm) and liver damage of class A or B. The patients were divided into SR (n=5361), RFA (n=5548), and PEI groups (n=2059). Overall survival and time to recurrence were compared among them.
RESULTS: Median follow-up was 2.16 years. Overall survival at 3 and 5 years was respectively 85.3%/71.1% in the SR group, 81.0%/61.1% in the RFA, and 78.9%/56.3% in the PEI. Time to recurrence at 3 and 5 years was 43.3%/63.8%, 57.2%/71.7%, and 64.3%/76.9%, respectively. On multivariate analysis, the hazard ratio for death was significantly lower in the SR group than in the RFA (SR vs. RFA:0.84, 95% confidence interval, 0.74-0.95; p=0.006) and PEI groups (SR vs. PEI:0.75, 0.64-0.86; p=0.0001). The hazard ratios for recurrence were also lower in the SR group than in the RFA (SR vs. RFA:0.74, 0.68-0.79; p=0.0001) and PEI groups (SR vs. PEI:0.59, 0.54-0.65; p=0.0001).
CONCLUSIONS: Our findings suggest that surgical resection results in longer overall survival and time to recurrence than either RFA or PEIin patients with HCC [corrected].
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178708     DOI: 10.1016/j.jhep.2012.11.009

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  101 in total

1.  Prognostic Significance of Treatment Strategies for the Recurrent Hepatocellular Carcinomas After Radical Resection.

Authors:  Ryo Saito; Hidetake Amemiya; Naohiro Hosomura; Hiromichi Kawaida; Suguru Maruyama; Hiroki Shimizu; Shinji Furuya; Hidenori Akaike; Yoshihiko Kawaguchi; Makoto Sudo; Shingo Inoue; Hiroshi Kono; Daiduke Ichikawa
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  A new device for fiducial registration of image-guided navigation system for liver RFA.

Authors:  Nobutaka Doba; Hiroyuki Fukuda; Kazushi Numata; Yoshiteru Hao; Kouji Hara; Akito Nozaki; Masaaki Kondo; Makoto Chuma; Katsuaki Tanaka; Shigeo Takebayashi; Norihiro Koizumi; Akira Kobayashi; Junichi Tokuda; Shin Maeda
Journal:  Int J Comput Assist Radiol Surg       Date:  2017-07-17       Impact factor: 2.924

3.  Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients.

Authors:  Jia-yan Ni; Lin-feng Xu; Hong-liang Sun; Jing-xing Zhou; Yao-ting Chen; Jiang-hong Luo
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-26       Impact factor: 4.553

4.  Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis.

Authors:  Baoxian Liu; Mengchao Wei; Furong Liu; Shuling Chen; Zhenwei Peng; Bin Li; Qian Zhou; Haibo Wang; Sui Peng; Ming Kuang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

5.  Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study.

Authors:  Víctor Molina; Jaime Sampson-Dávila; Joana Ferrer; Constantino Fondevila; Rafael Díaz Del Gobbo; David Calatayud; Jordi Bruix; Juan Carlos García-Valdecasas; Josep Fuster
Journal:  Surg Endosc       Date:  2017-12-07       Impact factor: 4.584

6.  Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study.

Authors:  Yumi Kosaka; Tomokazu Kawaoka; Yutaro Ogawa; Kei Amioka; Kensuke Naruto; Yuki Yoshikawa; Yuwa Ando; Yosuke Suehiro; Kenji Yamaoka; Yasutoshi Fujii; Shinsuke Uchikawa; Atsushi Ono; Masami Yamauchi; Michio Imamura; Keigo Chosa; Kazuo Awai; Yasushi Nagata; Kazuaki Chayama; Hiroshi Aikata
Journal:  Clin J Gastroenterol       Date:  2021-07-21

Review 7.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

Review 8.  Advances in managing hepatocellular carcinoma.

Authors:  Marielle Reataza; David K Imagawa
Journal:  Front Med       Date:  2014-05-08       Impact factor: 4.592

9.  Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.

Authors:  Jing-Hang Jiang; Zhe Guo; Hao-Feng Lu; Xiao-Bo Wang; Hao-Jie Yang; Fu-Quan Yang; Si-Yang Bao; Jian-Hong Zhong; Le-Qun Li; Ri-Rong Yang; Bang-De Xiang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

10.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.